Careers

Together with a team of skilled scientists and drug development professionals, VICO’s focus is on development of RNA modulating therapies for rare neurological disorders, with initial focus on SCA – Spinocerebellar ataxiaHD – Huntington’s disease and RETT syndrome.

The team has a long standing expertise in antisense oligonucleotide technology and a majority of our employees have worked most of their professional careers on RNA-modulating therapeutics for rare diseases. Our passion never dies in the mission to bring a therapy to the patients.

Interested in joining us?

Career opportunities

hide me

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

(Sr) Scientist (PhD) - Crystal Structure Biology

VICO Therapeutics BV is a Leiden-based biotech company with a focus on developing innovative RNA-modulating therapeutics for rare disorders that affect the brain, spinal cord and nerves.

Our strategy is to directly target the genetic source of the disease. Our tools are antisense oligonucleotides (AONs) that can correct defective genes at the RNA level. Our in-house precision chemistry generates safe and effective RNA-modulating AONs that can be applied to a broad spectrum of mutations and diseases. Our know-how and year-long experience ensures smart and efficient drug discovery and development.

VICO’s lead program is based on a single AON that applies to a series of neurodegenerative diseases caused by an expansion of  (CAG) trinucleotide repeats, including (but not limited to) Huntington’s disease (HD) and Spinocerebellar Ataxia type 1 (SCA1) and 3 (SCA3). Through the binding of this AON to the CAG repeat stretch, the translation into abnormally long and toxic polyglutamine (polyQ) stretches in proteins is hindered. This program advances towards a first-in-human trial in 2022.

More early programs in our pipeline focus on RNA-editing for RETT syndrome and RNAseH-mediated gene-silencing for Familial Alzheimer’s disease, but there is room for further expansion! Our Drug Discovery team is therefore looking for a:

Sr scientist (PhD) – Crystal structure biology

to help us set up new programs for other neurological disorders, implementing state-of-the-art technologies and chemistries. We offer ~1000 m2 of lab space attractively combining molecular biology and oligochemistry & manufacturing units with well-maintained equipment. VICO is a small, dynamic, and efficient organisation (currently 30 employees) and our team is positive and dedicated with continued focus on science and quality. We have a long track record of academic collaborations and publications in the field of antisense oligonucleotides for neuromuscular and neurodegenerative disorders, and genuinely value strong alliances with patient organisations.

Your responsibilities and tasks will include, but are not limited to, the following:

  • become an expert on RNA-modulating technologies, applying crystal structure modelling to support the design antisense oligonucleotides in the field of neurological disorders
  • monitor related scientific publications and patent applications and translate obtained insights to innovative design of oligonucleotides and experiments
  • support the Drug Discovery team and report to the CSO

Preferred profile:

  • a PhD degree in molecular biology or life science technologies
  • expertise in crystal structure modelling (required)
  • expertise in RNA modulating therapeutics
  • industry and IP mindset
  • excellent communication skills, fluency in English
  • strong scientific writing/presentation skills
  • a flexible and positive team player with a pro-active attitude

Interested?

Please send your resume and motivation letter to:

Vico Therapeutics BV

Email: careers@vicotx.com

 

NB: we collect personal data for selection purposes only. All personal data will be destroyed within 4 weeks after completion of the procedure.

Sr Scientists (PhD) – Molecular biology

VICO Therapeutics BV is a Leiden-based biotech company with a focus on developing innovative RNA-modulating therapeutics therapies for rare disorders that affect the brain, spinal cord and nerves.

Our strategy is to directly target the genetic source of the disease. Our tools are antisense oligonucleotides (AONs) that can correct defective genes at the RNA level. Our in-house precision chemistry generates safe and effective RNA-modulating AONs that can be applied to a broad spectrum of mutations and diseases. Our know-how and year-long experience ensures smart and efficient drug discovery and development.

VICO’s lead program is based on a single AON that applies to a series of neurodegenerative diseases caused by an expansion of  (CAG) trinucleotide repeats, including (but not limited to) Huntington’s disease (HD) and Spinocerebellar Ataxia type 1 (SCA1) and 3 (SCA3). Through the binding of this AON to the CAG repeat stretch, the translation into abnormally long and toxic polyglutamine (polyQ) stretches in proteins is hindered. This program advances towards a first-in-human trial in 2022.

More early programs in our pipeline focus on RNA-editing for RETT syndrome and RNAseH-mediated gene-silencing for Familial Alzheimer’s disease, but there is room for further expansion! Our Drug Discovery team is therefore looking for:

Sr scientists (PhD) – Molecular biology

to help us set up new programs for other neurological disorders, implementing state-of-the-art technologies and chemistries. We offer ~1000 m2 of lab space attractively combining molecular biology and oligochemistry & manufacturing units with well-maintained equipment. VICO is a small, dynamic, and efficient organisation (currently 30 employees) and our team is positive and dedicated with continued focus on science and quality. We have a long track record of academic collaborations and publications in the field of antisense oligonucleotides for neuromuscular and neurodegenerative disorders, and genuinely value strong alliances with patient organisations.

 

Your responsibilities and tasks will include, but are not limited to, the following:

  • become an expert on RNA-modulating technologies, applying antisense oligonucleotides in the field of neurological disorders
  • monitor related scientific publications and patent applications and translate obtained insights to innovative design of oligonucleotides and experiments
  • support the Drug Discovery team and report to the CSO

 

 

 

Preferred profile:

  • a PhD degree in molecular biology or life science technologies
  • expertise in neuroscience and neurodegenerative cell and mouse models
  • expertise in RNA modulating therapeutics
  • industry and IP mindset
  • excellent communication skills, fluency in English
  • strong scientific writing/presentation skills
  • a flexible and positive team player with a pro-active attitude

 

Interested?

Please send your resume and motivation letter to:

Vico Therapeutics BV

Email: careers@vicotx.com

 

NB: we collect personal data for selection purposes only. All personal data will be destroyed within 4 weeks after completion of the procedure.

Interested?

If you are interested in joining our mission to continuously discover, develop and deliver therapies then please send your full resume and application to careers@vicotx.com or submit it via the contact form.

    Attachment (pdf only. Max 2MB)